Biologics have revolutionized the therapeutic approach in infl ammatory bowel disease (IBD). Anti-tumor necrosis factor (anti-TNF) agents infl iximab and adalimumab currently constitute the major biological therapy in IBD. Additional anti-TNFs such as golimumab and other new biologics are currently being developed for both anti-TNF-naïve and -resistant patients. Th ese include anti-integrins (vedolizumab and etrolizumab), a JAK inhibitor (tofacitinib) and an anti-anti-interleukin (IL)-23 and IL-12 antibody (ustekinumab), among additional drugs in development. Th e following review discusses the indications, effi cacy and safety issues for these novel medications.
Introduction
During the last 15 years, the main progress in the fi eld of infl ammatory bowel disease (IBD) therapy has been related to development of anti-tumor necrosis factor (anti-TNF) agents. However, approximately 20% of patients do not respond to anti-TNFs, and over 30% eventually lose response [1, 2] . In addition, these drugs have been shown to increase the risk of infections and malignancies [3, 4] . Th ese, together with improved comprehension of biological pathways involved in the pathogenesis of the infl ammatory process in IBD, have led to the development of several new biological medications for Crohn's disease (CD) and ulcerative colitis (UC). A summary of the clinical data pertaining to the therapeutic agents discussed in this review is presented in Tables 1 and 2 .
Anti-TNF-α
Infl iximab and adalimumab are considered the mainstay of biological therapy in IBD for the last decade. Th ey have been shown to induce clinical and endoscopic remission in both CD and UC, to diminish exacerbations and surgery rates [5] [6] [7] [8] [9] . Certolizumab is a pegylated monoclonal IgG antibody against TNF-α. It was approved by the Food and Drug Administration (FDA) at 2008 for both induction and maintenance of remission in moderately-to-severely active CD, including patients who have previously lost response to infl iximab [10, [11] [12] [13] . It has been shown that lower drug levels and existence of antidrug antibodies correlate with loss of clinical and endoscopic response.
PURSUIT II evaluated golimumab maintenance therapy. Th e proportion of patients who maintained response to therapy until week 54 was higher in the 100-mg and 50-mg groups (49.7% and 47.0%, respectively) compared with patients who received placebo (31.2%; P<0.001 and P<0.01, respectively). Mucosal healing at weeks 30 and 54 was signifi cantly greater for patients receiving golimumab 100 mg (42.4%) compared with placebo (26.6%; P=0.002). Effi cacy in patients who received both intra-venous (IV) and sub-cutaneous (SC) induction therapy was similar [16] .
PURSUIT IV specifi cally compared IV and SC golimumab therapy. Effi cacy with single-dose golimumab IV induction was lower than that demonstrated in the SC induction study. At each corresponding IV and SC dose level (i.e. 1 mg/kg -100/50 mg, 2 mg/kg -200/100 mg and 4 mg/kg -400/200 mg), serum golimumab concentrations for the SC dose were higher than those for the IV dose at weeks 2, 4 and 6 [17] .
Adverse eff ects in the golimumab treatment groups are similar to those observed with other anti-TNFs, mainly severe infections. Data regarding combination therapy with an immunomodulator, eff ect of prior anti-TNF therapy, as well as complex disease phenotype are lacking [18] .
Immunogenicity
3/721 patients (0.4%) who had available sera samples, treated with golimumab at the PURSUIT I trial, were positive for antibodies to golimumab. Incidence of antibodies to golimumab until week 54 was 2.9% (32 out of 1103 patients) in the PURSUIT II study. Rate of antibody formation to golimumab among those who received concomitant immunomodulators was lower [1.1% (4 of 362)] compared with patients who were not receiving concomitant immunomodulators (3.8%, 28 of 741, P=0.013). Th ese fi ndings are in accordance with the rheumatological studies, which suggested that monotherapy was associated with a higher rate of antibody formation [19] . A recent study showed that the proportion of antibody positivity (15.2%, 5/33) in patients with rheumatoid arthritis (RA) was higher than in other studies (2.1%-8.1%). In ankylosing spondylitis, antibodies were detectable in only one (2.3%) patient, consistent with previous fi ndings that 4.1% of patients with ankylosing spondylitis developed immunogenicity [20] .
In summary, the PURSUIT trials have demonstrated that golimumab is eff ective for induction and maintenance of clinical and endoscopic remission in anti-TNF naïve UC patients. SC administration has been shown to be more eff ective than single IV dosage.
Integrin antagonists
Th ese are antibodies which target the leukocyte adhesion and traffi cking, thereby reducing infl ammation. Integrin antagonists have recently shown promising results in induction and maintenance of remission for both CD and UC patients [21] .
Natalizumab
Natalizumab blocks the α4 integrin on lymphocytes, which takes part in constituting the immune response in the central nervous system and the gut. Natalizumab induced and maintained remission in patients with moderate-to-severe CD [22] , but was found to increase the risk of progressive multifocal leukoencephalopathy (PML, approx. 1/300 patients), a central nervous system JC virus infection that can be lethal due to impaired central nervous system immune function. Antibodies to JC virus, use of concomitant immunosuppressives and increased duration of natalizumab treatment have been shown to increase PML risk [23] . Natalizumab was temporarily withdrawn from the market but was reintroduced in 2006 in the USA using a surveillance program [24] .
Vedolizumab
Vedolizumab is a humanized monoclonal antibody that recognizes the gut-specifi c α4β7 subunit. It has been approved in moderate-to-severe UC or CD. GEMINI I trial demonstrated that vedolizumab is eff ective and safe for induction and maintenance in moderate-to-severe UC. Rates of mucosal healing were 40.9% (92/225 patients) with vedolizumab and 24.8% (37/149) with placebo (P=0.001). At week 52, patients who continued receiving the drug were more likely to achieve clinical remission than were those randomly assigned to switch to placebo (41.8%, 44.8% for vedolizumab every 8 and 4 weeks vs. 15.9% placebo patients).
No clear diff erences in effi cacy were observed between the two vedolizumab regimens (every 8 or 4 weeks). Concomitant glucocorticoids or immunomodulators or previous therapy with anti-TNFs did not substantively aff ect outcome [25] . No signifi cant diff erences were observed among the study groups in the rates of adverse events. No cases of PML occurred [26] .
A network meta-analysis showed that in patients with moderate-to-severe UC, naïve to biologics, vedolizumab has similar effi cacy to infl iximab, adalimumab and golimumab, for induction and maintenance. Only vedolizumab had a lower incidence of serious adverse events compared with placebo [26, 27] .
GEMINI II trial evaluated vedolizumab therapy among CD patients. Vedolizumab-treated active CD patients were more likely than patients receiving placebo to undergo clinical remission at week 6 (32/220, 14.5% vs. 10/148, 6.8%, P=0.02), but not a CD activity index (CDAI)-100 response (P=0.23). At week 52, 60/154 patients (39.0%) treated with vedolizumab every 8 weeks and 56/154 patients (36.4%) on vedolizumab every 4 weeks were in clinical remission, compared with 33/153 patients (21.6%) under placebo (P<0.001 and P=0.004 respectively). Serious infections were identifi ed in 5.5% of vedolizumab therapy patients compared with 3.0% of the patients under placebo. No cases of PML or malignancies were identifi ed [28] [29] [30] [31] .
Since the GEMINI trials, several cohort studies have followed UC and CD vedolizumab therapy patients and have shown a favorable profi le of effi cacy and limited adverse events. Shelton et al followed 172 patients (107 CD, 59 UC, and 6 unclassifi ed IBD). Only 35.5% of them were eligible for the GEMINI trials and 70.9% failed at least two anti-TNFs. In CD, 48.9% and 23.9%; and in UC, 53.9% and 29.3% had clinical response and clinical remission at week 14, respectively. Adverse events occurred in 10.5% [29] . Vivio et al have recently demonstrated improvement in Harvey-Bradshaw Index and partial MAYO scores in 102 UC and CD patients by week 14 (P<0.01, <0.001 respectively), with 90% of patients maintaining therapy by week 14. With respect to serious adverse events, 3 of the UC patients had undergone colectomy due to non-remitting disease, 5 of the CD patients had undergone CD-related surgeries and 2 other CD patients had severe infectious complications [32] .
Immunogenicity
Of 620 vedolizumab-treated UC patients, 23 (3.7%) had samples positive for anti-vedolizumab antibodies at any time, and 6 (1.0%) had samples that were persistently positive through week 52. Concomitant immunosuppressives were associated with decreased immunogenicity. Of 814 CD patients receiving vedolizumab, 33 (4.1%) had at least one antibody positive sample. Unlike among UC patients, concomitant immunosuppressives decreased immunogenicity [33] .
In conclusion, vedolizumab has been proven eff ective in moderate-to-severe UC and CD, including nonresponders to TNF antagonists. No clear diff erence in effi cacy has been observed with 8-versus 4-week interval between doses. Concurrent treatment with glucocorticoids or immunosuppressants or previous treatment with TNF antagonists did not aff ect the outcome. Rate of serious adverse events was similar to placebo.
Etrolizumab
Etrolizumab is an IgG1 humanized monoclonal antibody that binds the β7 subunit of the α4β7 and the αEβ7 integrin heterodimers in the intestine. Th e safety and pharmacology of etrolizumab were evaluated in a randomized phase 1 study in patients with moderate-to-severe UC [34] . In a subsequent phase 2 study, patients with moderate-to-severe active UC were 
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treated SC with three monthly doses of 100 mg, a loading dose of 420 mg and then 300 mg, or placebo. Clinical remission occurred at week 10 in 20.5% of patients in the etrolizumab 100 mg group (P=0.004), 10.3% of patients in the etrolizumab 420 mg loading dose group (P=0.048), and no patients in the placebo group. Data from the phase II study show that concomitant use of steroids and immunomodulators and anti-TNF-naïve status were signifi cantly associated with higher remission rates, although no signifi cant diff erences in mucosal healing rate (defi ned as MAYO score=0) were identifi ed [35] . More studies are needed to confi rm these data due to the small total sample size (n=38, 81 etrolizumab therapy patients in phase I and II studies) [36] .
Immunogenicity
Of 81 patients in the phase II study, four (5%) had detectable antidrug antibodies aft er treatment. Occurrence of adverse events did not seem to be associated with the presence of antidrug antibodies [35] .
Ustekinumab
Ustekinumab is a human monoclonal immunoglobulin that targets P40, the shared subunit of the interleukins (IL)-12 and IL-23 [37] . It has been shown to be eff ective in psoriasis and psoriatic arthritis (PHOENIX and P-SUMMIT phase III trials respectively), and is now evaluated for its effi cacy in CD [38] . In the phase IIb CERTIFI trial 526 CD patients who failed anti-TNFs were randomized to either ustekinumab or placebo. Clinical response at week 6 was achieved in 36.6%, 34.1%, and 39.7% of patients receiving an IV dose of 1, 3, or 6 mg/kg, respectively, and in only 23.5% of those treated with placebo (P=0.005 for 6 mg/kg vs. placebo). Week 6 clinical remission was similar for the ustekinumab groups and placebo. 69.4% of ustekinumab maintenance therapy patients (90 mg SC at weeks 8 and 16) maintained their response at week 22, as compared to 42.5% in those randomized to receive placebo (P<0.05). Due to the small numbers of patients in the dose subgroups, the optimal dosage of ustekinumab is unclear. Fift y patients were evaluated for mucosal healing. In the placebo group, 1/9 reached mucosal healing, compared with 8/41 (19.5%) of ustekinumab patients (P=1.00) [39, 40] .
In a real-life cohort of 38 severe CD patients who failed anti-TNFs, an initial clinical response to SC ustekinumab was observed in 73.7% of the patients. Dose escalation was needed in 47.7% and was successful in 61.1% of the patients [41] . Th e UNITI I phase 3 trial had confi rmed the results of the CERTIFI among moderate-to-severe CD patients refractory to one or more anti-TNFs; IV ustekinumab was demonstrated to induce clinical response and remission and was well tolerated throughout induction. Clinical response at week 6 was observed in 33.7% of the 6 mg/kg and 34.3% of the 130 mg groups versus 21.5% in the placebo group (P=0.003 and 0.002, respectively). Clinical remission (CDAI <150) at week 8 was observed in 20.9% of the 6 mg/kg ustekinumab group and 15.9% of the 130 mg group versus 7.3% of placebo patients (P<0.001, P=0.003, respectively) In a recent retrospective study by Wils et al, 79 patients (65%) improved within 3 months of starting ustekinumab. Concomitant immunomodulators increased the odds of clinical improvement (odds ratio, 5.43; 95% confi dence interval, 1.14-25.77; P=0.03). Over a median follow up of 9.8 months, the cumulative probabilities that patients maintained clinical benefi t for 6 and 12 months aft er induction were 93% and 68%, respectively [42] .
In the induction phase of the CERTIFI trial, infection rates were also similar between ustekinumab and placebo patients. In the maintenance phase (approximately 25 weeks of follow up) neither deaths, nor serious opportunistic infections were identifi ed. Th e long-term safety profi le of ustekinumab has been evaluated in the treatment of psoriasis as well [43] . Pooling safety data from 4 clinical trials of ustekinumab for psoriasis, a total of 3117 patients were given at least one dose of ustekinumab. Serious adverse events rates at fi ve years at year 5 were 7.0 and 7.2 per 100 patients years; serious infections rates were 0.98 and 1.19. No increase in adverse events, overall mortality or malignancies was identifi ed, compared with an age-matched and sex-matched US population [40] . One case of demyelination in a patient receiving ustekinumab for CD has been recently reported [44] . Ongoing phase 3 clinical trials in CD are underway and the results are eagerly awaited. In recently presented results from the UNITI II, ustekinumab doses 6 mg/kg and 130 mg, showed signifi cant improvement versus placebo in CDAI, C-reactive protein (CRP), and fecal calprotectin [45] .
Immunogenicity
In the phase 2b CERTIFI trial, 427 ustekinumab-treated patients had available serum samples for analysis. Th ree (0.7%) had positive antibodies to ustekinumab at week 36. A recent publication on psoriasis showed that at weeks 16 and 28 serum levels of ustekinumab did not correlate with response status [46] . Nevertheless, a study on refractory CD patients, reported in an abstract form, stated that ustekinumab >4.5 μg/mL, compared to lower levels, increased endoscopic response (81.3% vs. 25%, P=0.008) and the combined outcome of steroid-free clinical remission and endoscopic response (50% vs. 15%, P=0.024) [47] .
In summary, ustekinumab is an antibody to a subunit of cytokines IL-12 and IL-23. It has been shown to induce clinical response in approximately 37% of CD patients who failed antiTNFs. Sustained response and mucosal healing have been equivocal, perhaps due to limited data so far.
JAK kinase inhibitors Tofacitinib
Tofacitinib is an oral inhibitor of JAK 1, 2 and 3, expected to block signaling involving gamma-chain-containing cytokines including IL -2, -4, -7, -9, -15 and -21. Tofacitinib has been recently approved for treatment of RA, and is under evaluation for both UC and CD. Tofacitinib has been demonstrated to be eff ective in patients with moderately-to-severely active UC [48] . A major phase II study by Sandborn et al enrolled 194 patients with moderately-to-severely active UC to oral tofacitinib 0.5 mg, 3 mg, 10 mg, 15 mg, or placebo. Tofacitinib was administered for 8 weeks twice daily without concomitant immunomodulators or biologics. Th ere was a dose-dependent eff ect with clinical response observed in 32%, 48%, 61%, and 78% of patients treated with tofacitinib 0.5 mg, 3 mg, 10 mg, and 15 mg doses, respectively, compared with 42% of patients under placebo (P<0.001 for 15 mg). Clinical remission at week 8 was observed in 13%, 33%, 48%, 41% of patients treated with tofacitinib 0.5 mg, 3 mg, 10 mg, and 15 mg doses (P=0.001 for 10 mg and 15 mg), respectively, compared with 10% under placebo. Endoscopic remission at 8 weeks occurred in 1 of 48 patients (2%) receiving placebo, compared with 3 of 31 (10%) receiving 10 mg of tofacitinib (P<0.001), and 13 of 49 (27%) receiving 15 mg of tofacitinib (P<0.001). In the phase 2 randomized controlled trial of tofacitinib in CD, 139 patients with moderate-to-severe CD, who failed immunomodulators or biologics were randomized to tofacitinib 1 mg, 5 mg, 15 mg, or placebo twice daily for a total of 4 weeks. Th e primary endpoint of clinical response was achieved in 36%, 58%, and 46% of patients in the 1 mg, 5 mg, and 15 mg tofacitinib arms respectively, which was not signifi cantly diff erent from the 47% response rate in the placebo group. Clinical remission rates were also similar among tofacitinib and placebo groups. Notwithstanding, infl ammatory marker levels (CRP and fecal calprotectin) from baseline to week 4 were lower among tofacitinib patients (especially higher doses of 10 or 15 mg) [48] .
Th e adverse eff ect profi le for tofacitinib appears to be similar to other biologics, including bacterial, fungal, and viral infections and solid malignancies and lymphoma. Specifi cally, a large phase 3 RA study demonstrated higher rates of serious infections in the tofacitinib 5 and 10 mg groups compared with placebo (6 vs. 0 events). In a study on kidney transplant patients [49] , anemia, neutropenia and post-transplant lymphoproliferative disorder occurred more frequently in tofacitinib patients compared with cyclosporine [50] . In addition, in RA as well as UC and CD studies, a dose-dependent increase in both LDL and HDL cholesterol concentrations has been observed at 8 weeks with tofacitinib, which reversed aft er discontinuation [48] .
Immunogenicity
To the best of our knowledge, immunogenicity of tofacitinib has not been studied so far. In conclusion, tofacitinib is an orally administered JAK inhibitor. In phase 2 trials, 15 mg of tofacitinib showed signifi cantly higher rates of clinical remission compared with placebo (approx. 40%) in UC patients. With respect to CD, no clear clinical benefi t could be demonstrated.
Concluding remarks
Nowadays, biological therapy is considered the mainstay for moderate-to-severe UC and CD. Th e anti-TNFs infl iximab and adalimumab have been extensively used and shown to induce clinical and endoscopic remission. Nevertheless, many do not respond initially or lose response. Aft er certolizumab, golimumab is the fourth and last anti-TNF currently available for IBD. It has been shown to be eff ective for induction and maintenance of clinical and endoscopic remission in anti-TNF naive UC patients (approx. 50% sustained remission). Vedolizumab is an anti-integrin, an integral part of the leukocyte adhesion and traffi cking system in the gut. It has been proven eff ective in moderate-to-severe UC and CD (approx. 40% sustained remission rates), including non-responders to TNF antagonists. Etrolizumab is another anti-integrin, currently studied at phase 3 trials for UC. Phase I and II studies demonstrated that with optimal dosing, remission rate is approximately 20%. Data are lacking as to several key parameters such as mucosal healing rate and response in anti-TNF failure. Another new biologic is ustekinumab, an antibody to a subunit of IL-12 and IL-23. It has been shown to induce clinical response in approx. 37% of CD patients who failed anti-TNFs. Finally, tofacitinib is an orally administered JAK inhibitor; 15 mg of tofacitinib showed signifi cantly higher rates of clinical remission as compared to placebo (approx. 40%) in UC patients. Several other biologics are underway; PF-00547659, a monoclonal antibody against MAdCAM-1 and several orally administered biologics, including avaxia, an anti-TNF, vercirnon, an anti-CCR 9, and SMAD7, an antisense oligonucleotide which suppresses transforming growth factor β1. Effi cacy of these formulations for both CD and UC is currently being studied [24] .
